Pfizer's BRAFTOVI Regimen Shows Significant Survival Benefits in Metastatic Colorectal Cancer
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
Businesswire
Image: Businesswire
Pfizer's BRAFTOVI regimen, in combination with cetuximab and chemotherapy, significantly improves median progression-free survival in patients with metastatic colorectal cancer harboring BRAF V600E mutations. The Phase 3 BREAKWATER trial revealed a nearly doubled survival rate, with a 56% reduction in disease progression risk and a 44% reduction in mortality risk.
- 01The BRAFTOVI regimen achieved a median progression-free survival of 15.2 months, compared to 8.3 months for the comparator group.
- 02Patients treated with BRAFTOVI experienced a 56% reduction in the risk of disease progression or death (HR 0.44).
- 03The overall survival benefit showed a 44% reduction in mortality risk for patients on the BRAFTOVI regimen (HR 0.56).
- 04At 18 months, 72% of patients on the BRAFTOVI regimen were expected to be alive, compared to 54.5% for the comparator group.
- 05BRAFTOVI is the only FDA-approved targeted therapy specifically for BRAF V600E-mutant metastatic colorectal cancer.
Advertisement
In-Article Ad
Pfizer Inc. has announced promising results from its Phase 3 BREAKWATER trial, which evaluated the BRAFTOVI® (encorafenib) regimen for patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). The trial's Cohort 3 demonstrated that the BRAFTOVI combination with cetuximab and fluorouracil-based chemotherapy significantly improved median progression-free survival (PFS) to 15.2 months, nearly double the 8.3 months seen with traditional chemotherapy. Additionally, the regimen resulted in a 56% reduction in the risk of disease progression or death and a 44% reduction in mortality risk. At 18 months, 72% of patients on the BRAFTOVI regimen were alive compared to 54.5% in the comparator group. The safety profile of BRAFTOVI remained consistent with previous findings, with no new safety signals identified. This regimen is now recognized as the standard of care for patients with this specific mutation, marking a significant advancement in the treatment landscape for metastatic colorectal cancer.
Advertisement
In-Article Ad
The approval of BRAFTOVI as a targeted therapy offers new hope for patients with BRAF V600E-mutant metastatic colorectal cancer, a group previously lacking effective treatment options.
Advertisement
In-Article Ad
Reader Poll
What do you think about the new treatment options for metastatic colorectal cancer?
Connecting to poll...
More about Pfizer Inc.
Read the original article
Visit the source for the complete story.